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mplications of Estimating
oronary Heart Disease
isk in the U.S. Population*
aniel S. Berman, MD, FACC,†
athan D. Wong, PHD, FACC‡
rvine and Los Angeles, California
iven the profound impact of coronary heart disease
CHD) on the health of the adult population of the U.S. as
ell as on health care costs, it is important to estimate the
ational burden of CHD. In this issue of the Journal, Ford
t al. (1) have nicely described the extent of the population
t significant risk for CHD and how this varies by age
roup, ethnicity, and gender. In 2001, the National Cho-
esterol Education Program (NCEP) Expert Panel on
etection, Evaluation, and Treatment of High Blood Cho-
esterol in Adults (Adult Treatment Panel III [ATP/III]),
nown as the NCEP/ATP III (2), provided recommenda-
See page 1791
ions for treatment of dyslipidemia according to the category
f risk based on Framingham Heart Study risk prediction
lgorithms, with the intensity of treatment being related to
isk categories. Ten-year risk of CHD, defined as CHD
eath or myocardial infarction, was divided into low
10%), intermediate (10% to 20%), and high (20%),
ased on modifications of the risk prediction equations
rovided by the Framingham Heart Study. Those with
iabetes or other CHD risk equivalents (e.g., peripheral
rterial disease, symptomatic carotid disease, and stroke) are
ssigned to the high-risk group. From 1988 to 1994, the
hird National Health and Nutrition Examination Survey
NHANES III) collected data needed to estimate risk of
HD, including measurements of total and high-density
ipoprotein cholesterol, systolic blood pressure, cigarette
moking, and historical information about CHD and CHD
isk equivalents (diabetes, stroke, or peripheral vascular
isease).
Ford et al. (1) have applied the NCEP/ATPIII risk
ategorization to the data collected from the 1988 to 1994
HANES population and projected what these findings
mply for the adult U.S. population of 2000 (1). This
nformation provides a framework for estimating the num-
er of patients needing treatment according to low-,
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Departments of Imaging and Medicine, Cedars-Sinai Medical Center,
os Angeles, California, and the ‡Heart Disease Prevention Program, Division of
rardiology, University of California, Irvine, California.ntermediate-, or high-risk treatment guidelines. Because
reatment guidelines such as the NCEP/ATP III for dys-
ipidemia (2) and Joint National Committee for hyperten-
ion (3) suggest that the intensity of treatment depends on
atients’ risk and/or presence of vascular disease or target
rgan damage, appropriate classification of patients is of
mportance to the entire health care system for estimating
eeded health care resources.
The authors found that of 159 million adults between 20
nd 79 years of age in the U.S. in 2000, an estimated 72.6%
ere at low risk, 11.9% were at moderate risk, and 15.6%
ere at high risk (20% calculated risk) or already had
HD or a CHD risk equivalent, thus warranting treatment
ccording to secondary prevention guidelines. A higher
roportion of men (17.3%) than women (14.1%) fit within
his category, and 30% of the population age 60 to 69 years
nd 43.3% of those age 70 to 79 years were classified as high
isk. Given significant increases in the prevalence of diabetes
ince this time, re-estimation of risk using recently released
HANES IV data from 1999 to 2000 is likely to yield an
ven greater proportion of high-risk patients. Moreover, the
uthors note that the proportion of patients in the high-risk
roup was probably further underestimated because nonin-
asive imaging tests for identifying subclinical high-risk
atients were not included in the NHANES III data. The
nding that 11.9% of the overall population (and approxi-
ately one-third of those age 60 years or greater) were at
ntermediate risk is of particular interest in considering the
otential health resource utilization because it is widely held
hat additional testing for the purposes of more accurate risk
tratification may be indicated in this group (4).
From a practical standpoint, the treating physician needs
o understand the limitations of these risk estimates from
he large epidemiologic studies. Although risk estimates
ork very effectively in populations, variation of estimated
isk leads to misclassification of true risk in individual
atients. Although this consideration has implications for
ll levels of risk (i.e., some patients classified as high risk
ay not actually be at high risk), the most difficult problems
or treating physicians occur in the intermediate-risk group;
or example, when a patient presents with intermediate risk,
he NCEP/ATP III would typically recommend a low-
ensity lipoprotein cholesterol goal of 130 mg/dl. The
CEP/ATP III has suggested that the presence of signif-
cant subclinical disease (e.g., coronary calcium score 75th
ercentile for age and gender, ankle-brachial index 0.9, or
arotid intimal thicknesses 1 mm) would warrant strati-
cation into the next higher risk category (e.g., as a CHD
isk-equivalent warranting that the low-density lipoprotein
holesterol goal be 100 mg/dl). The recent European
ociety of Cardiology guidelines (5) also suggest further
esting (including magnetic resonance imaging, computed
omography, carotid ultrasound, and detection of left ven-
ricular hypertrophy by electrocardiogram or echocardiog-
aphy) may help to define those at higher risk of future
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Editorial Comment May 19, 2004:1797–8ardiovascular events with greater precision than models
ased on classical risk factors. Also, the Bethesda Confer-
nce has indicated that noninvasive imaging and detection
ay be useful for those in the range of 6% to 20% 10-year
isk of CHD (4). For example, among persons with the
etabolic syndrome but without diabetes, many persons
ould fall within this range of risk. We recently reported
hat although 21% of persons with the metabolic syndrome
but without diabetes) had a calculated 10-year risk of CHD
f 20%, 25% had coronary calcium scores 75th percen-
ile, and 41% had either or both, indicating a significantly
reater number of high-risk individuals potentially warrant-
ng aggressive risk factor modification may be identified
hrough subclinical disease testing (6).
Regarding the accuracy of the estimates by Ford et al. (1),
here are several areas of potential concern beyond those
oted above. First, as acknowledged by the authors, there
ould be an underestimation of risk due to the reliance (at
east in part) of self-reporting of cardiovascular conditions,
iabetes, and smoking. Second, the risk assessments do not
ake into account family history of early CHD, some of the
ey metabolic syndrome risk factors (such as abdominal
besity or triglycerides), or serum markers now frequently
btained as part of standard risk assessment (e.g., high
ensitivity C-reactive protein). Third, there could be error in
nderestimation of risk of CHD in women. Although
0-year estimated risk of CHD may be substantially lower
n women than in men, the lifetime risk of CHD remains
ubstantial in women.
Despite these limitations, the estimates by Ford et al. (1)
ave demonstrated that a large proportion of the U.S.
opulation is at high or intermediate risk. This suggests a
all to action to: 1) identify those patients at high risk for
hom numerous clinical trials have documented that ag-
ressive risk factor intervention strategies will cost-
ffectively reduce risk of future CHD events; 2) considerow we can better stratify risk for individuals at intermedi-
te risk of CHD events in whom novel risk factors or testing
or subclinical atherosclerosis may provide the information
ecessary to identify those warranted for more aggressive
isk-factor intervention; and 3) further public health and
opulation-based approaches, such as implementation of
ietary and other lifestyle strategies, health-focused adver-
ising in the media, and other strategies aimed at shifting
he overall distribution curve of population risk of CHD
ownward.
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edars-Sinai Medical Center, Imaging, 8700 Beverly Boulevard,
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